Could a Bone-Seeking radiation drug catch prostate cancer early?
NCT ID NCT04206319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests Radium-223 in men whose prostate cancer has returned after initial treatment, but only shows up as rising PSA levels in blood—not on standard scans. The goal is to see how the drug affects the immune system and PSA levels. Participants receive up to 6 doses of Radium-223 and are followed for life.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICAL RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States